Recommendations for the registration of drugs used in the treatment of osteoarthritis: An update on biochemical markers

Osteoarthritis and Cartilage

Volumn 9, Issue 4, 2001, Pages 289-293

  Vignon, E ^a   Garnero, P ^b   Delmas, P ^c   Avouac, B ^d   Bettica, P ^e   Boers, M ^f   Ehrich, E ^g   MacKillop, N ^h   Rovati, L ⁱ   Serni, U ^j   Spector, T ^k   Reginster, J Y ^l  

^a UNIVERSITÉ LYON 1   (France)

^b Synarc   (France)

^c HEH   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e PROCTER AND GAMBLE COMPANY   (United States)

^f University Hospital   (Netherlands)

^g Merck   (United States)

^h PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

ⁱ Rotta Research Laboratorium   (Italy)

^j Divisione di Reumatologia   (Italy)

^k ST THOMAS HOSPITAL   (United Kingdom)

^l UNIVERSITY OF LIÈGE   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTIBODY; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; CHONDROITIN SULFATE; COLLAGEN TYPE 2; EPITOPE; HYALURONIC ACID; KERATAN SULFATE; MATRIX METALLOPROTEINASE; METALLOPROTEINASE; OSTEOCALCIN; PROTEOGLYCAN; PYRIDINIUM DERIVATIVE; PYRIDINOLINE; SIALOPROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE;

ARTICLE; CLINICAL FEATURE; CLINICAL RESEARCH; DISEASE COURSE; DRUG SCREENING; HUMAN; METHODOLOGY; OSTEOARTHRITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PUBLICATION; RADIOGRAPHY; RADIOLOGY; RHEUMATIC DISEASE; RISK ASSESSMENT;

EID: 0034996034     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1053/joca.2000.0387     Document Type: Editorial

References (43)

1. Altman RD, Brandt K, Hochberg M, Moskowitz R. Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Osteoarthritis Cart. 4:1996;217-243.
2. Ann Rheum Dis. 55:1996;552-557.
3. Bellamy N, Kirwan J, Boers M, Brooks P, Strand V, Tugwell P. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol. 24:1997;799-802.
4. Bellamy N. Clinical trials design: structure modifying agents for osteoarthritis. Future guidelines: areas for development. Osteoarthritis Cart. 7:1999;424-426.
5. Vignon E, Conrozier T, Piperno M, Richard S, Carrillon Y, Fantino O. Radiographic assessment of hip and knee osteoarthritis. Recommendations: recommended guidelines. Osteoarthritis Cart. 7:1999;434-436.
6. Boers M, Brooks P, Strand V, Tugwell P. The OMERACT filter for outcome measure in rheumatology. J Rheumatol. 25:1998;198-199.
7. Lohmander LS, Dahlberg L, Ryd L, Heinegard D. Increased levels of proteoglycan fragments in knee joint injury. Arthritis Rheum. 32:1989;1434-1442.
8. Lohmander LS, Hoerrner LA, Lark MW. Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum. 36:1993;181-189.
9. Thonar EJ, Lenz ME, Kintworth GK, Caterson B, Patchman LM, Glickman P. Quantification of keratan sulfate in blood as a marker of cartilage metabolism. Arthritis Rheum. 28:1985;1367-1376.
10. Sweet MBE, Coelho A, Schnitzer CM, Schnitzer TJ, Lenz ME, Jaim I. Serum keratan sulfate levels in osteoarthritis patients. Arthritis Rheum. 31:1988;648-652.
11. Bleasel JF, Poole AR, Heinegard D, Saxne T, Holderbaum D, Ionescu M. Changes in serum cartilage marker levels indicate altered cartilage metabolism in families with the osteoarthritis-related type II collagen gene COL2A1 mutation. Arthritis Rheum. 42:1999;39-45.
12. Poole AR, Ionescu M, Swan A, Dieppe PA. Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of the cartilage proteoglycan aggrecan. Implications for pathogenesis. J Clin Invest. 94:1994;25-33.
13. Belcher C, Yaqub R, Fawthriop F, Bayliss M, Doherty M. Synovial fluid chondroitin and keratan sulfate epitopes, glycosaminoglycans and hyaluronan in arthritic and normal knees. Ann Rheum Dis. 56:1997;299-307.
14. Ishiguro N, Ito T, Iwata H, Jugessur H, Ionescu M, Poole R. Relationship of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover. Arthritis Rheum. 42:1999;129-136.
15. Lohmander LS, Ionescu M, Jugessur H, Poole AR. Changes in joint cartilage aggrecan after knee injury and osteoarthritis. Arthritis Rheum. 42:1999;534-544.
16. Lohmander LS, Saxne T, Heinegard DK. Release of cartilage oligomeric matrix protein (COMP) into joint fluid after knee injury and in osteoarthritis. Ann Rheum Dis. 53:1994;8-13.
17. Sharif M, Saxne T, Shepstone L, Kirwan JR, Elson CJ, Heinegard D. Relationship between serum cartilage oligomeric matrix protein levels and disease progression in osteoarthritis of the knee joint. Brit J Rheumatol. 34:1995;306-310.
18. Conrozier T, Saxne T, Shan Sei Fan C, Mathieu P, Tron A-M, Heinegard D. Serum concentrations of cartilage oligomeric matrix protein and bone sialoprotein in hip osteoarthritis: A one year prospective study. Ann Rheum Dis. 9:1998;527-532.
19. Petersson IF, Boegard T, Dahlstrom J, Svensson B, Heinegard D, Saxne T. Bone scan and serum markers of bone and cartilage in patients with knee pain and osteoarthritis. Osteoarthritis Cart. 6:1998;33-39.
20. Clark AG, Jordan JM, Vilim V, Renner JB, Dragomir AD, Luta G. Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity. Arthritis Rheum. 42:1999;2356-2364.
21. Eyre DR, Shao P, Vosberg-Smith K, Weis M, Shaffer K, Yoshihara P. Cross-linked telopeptides from collagen types I, II and III in human urine. J Bone Miner Res. S1:1995;S413.
22. Moskowitz RW, Holderbaum D, Atley LM, Eyre DR. Type II C-telopeptide 2B4 epitope is a marker for cartilage degradation in familial osteoarthritis. Arthritis Rheum, 41:1998;S352.
23. Woodworth TG, Otterness IG, Johnson K, Pickering E, Saltarelli MJ. Urinary type II collagen neoepitope (uTIINE) in osteoarthritis (OA) is associated with disease severity. Arthritis Rheum, 42:1999;S258.
24. Lohmander LS, Yoshihara Y, Roos H, Kobayashi T, Yamada H, Shinmei M. Procollagen II C-propeptide in joint fluid: changes in concentration with age, time after knee injury, and osteoarthritis. J Rheumatol. 23:1996;1765-1769.
25. Nelson F, Dahlberg L, Laverty S, Reiner A, Pidoux I, Ionescu M. Evidence for altered synthesis of type II collagen in patients with osteoarthritis. J Clin Invest. 12:1998;2115-2125.
26. Balblanc JC, Conrozier T, Hartmann D, Mathieu P, Richard M, Vignon E. Acide hyaluronique et phopholipase A2 sériques dans une population arthrosique. Rev. Rhum. 58:1991;857-862.
27. Sharif M, George L, Shepstone J, Knudson W, Thonar EJ-MA, Cushnagan J. Serum hyaluronic acid level as a predictor of disease progression in osteoarthritis of the knee. Arthritis Rheum. 38:1995;760-767.
28. Laurent TC, Larent UBG, Fraser RE. Serum hyaluronan as a disease marker. Ann Med. 28:1996;241-253.
29. Spector TD, Hart DJ, Nandra D, Doyle DV, MacKillop N, Gallimore JR. MBLow-levels increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum. 40:1997;723-727.
30. Conrozier T, Chappuis-Cellier C, Richard M, Mathieu P, Richard S, Vignon E. Increase C-reactive protein levels by immunonephelometry in patients with rapidly destructive hip osteoarthritis. Rev Rhum (Engl. Ed.). 12:1998;759-765.
31. Johansen JS, Jensen HS, Price PA. A new biochemical for joint injury. Analysis of YKL-40 in serum and synovial fluid. Brit J Rheumatol. 32:1993;949-955.
32. Johansen JS, Hvolris J, Hansen M, Backer V, Lorenszen I, Price PA. Serum YKL-40 levels in healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Brit J Rheumatol. 35:1996;553-559.
33. Harvey S, Weisman M, O'Dell J, Scott T, Krusemeier M, Visor J. Chondrex: a new marker of joint disease. Clin Chem. 44:1998;509-516.
34. Naito K, Takahashi K, Kushida K, Suzuki M, Ohishi T, Miura M. Measurement of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in patients with knee osteoarthritis: comparison with generalized osteoarthritis. Rheumatology. 38:1999;510-515.
35. Petersson IF, Boegard T, Svensson B, Heinegard D, Saxne T. Changes in cartilage and bone metabolism identified by serum markers in early osteoarthritis of the knee joint. Brit J Rheumatol. 37:1998;46-50.
36. Thompson PW, Spector TD, James IT, Henderson E, Hart DJ. Urinary collagen crosslinks reflect the radiographic severity of knee osteoarthritis. Brit Med J. 31:1992;759-761.
37. Astbury C, Bird HA, McLaren AM, Robin SP. Urinary excretion of pyridinium crosslinks of collagen correlated with joint damage in arthritis. Brit J Rheumatol. 33:1994;11-15.
38. Hellio le Graverand MP, Tron AM, Dallard MC, Richard M, Uebelart D, Vignon E. Assessment of urinary hydroxypyridinium crosslink measurements in osteoarthritis. Brit J Rheumatol. 35:1996;1091-1095.
39. Saxne T, Heinegard D, Wollheim FA, Petterson H. Difference in cartilage proteoglycan level in synovial fluid in early rheumatoid arthritis and reactive arthritis. The Lancet. 2:1985;127-128.
40. Forslind K, Eberhardt K, Jonsson A, Saxne T. Increased serum concentration of cartilage oligomeric matrix protein. A prognostic marker in early rheumatoid arthritis. Brit J Rheumatol. 31:1992;593-598.
41. Mansson B, Carey D, Alini M, Ionescu M, Rosenberg LC, Poole AR. Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Invest. 95:1995;1071-1077.
42. Iwase T, Hasegawa Y, Ishiguro N, Ito T, Iwasada S, Kitamura S. Synovial fluid cartilage metabolism marker concentrations in osteonecrosis of the femoral head compared with osteoarthrosis of the hip. J Rheumatol. 25:1997;527-531.
43. Saxne T, Heinegard D. Synovial fluid analysis of two groups of proteoglycan epitopes distinguished early and late cartilage lesions. Arthritis Rheum. 35:1992;385-390.